We're unable to sign you in at this time. Please try again in a few minutes.
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
In This Issue of JAMA |

Highlights FREE

JAMA. 2016;315(19):2041-2043. doi:10.1001/jama.2015.14266.
Text Size: A A A
Published online


Animal data and clinical studies demonstrate neuroprotective effects of erythropoietin (EPO). In a randomized placebo-controlled trial that enrolled 448 very preterm infants, Natalucci and colleagues assessed the effect of prophylactic early high-dose recombinant human EPO (rhEPO) on neurodevelopmental outcomes at age 2 years. Neurodevelopmental outcome data were available for 365 infants. The authors found no significant differences in neurodevelopmental outcomes among infants who received rhEPO compared with those who received placebo.

Among incapacitated critically ill patients, surrogate decision makers’ unrealistic expectations about prognosis can be a barrier to quality end-of-life care. In a prospective cohort study involving 229 surrogate decision makers and 99 physicians of 174 critically ill patients at high risk of death, White and colleagues found that physician-surrogate discordance about the patients’ likelihood of survival to hospital discharge was common. Discordance was associated with surrogates misunderstanding physicians’ prognostic expectations and surrogates’ systematically different beliefs about the patient’s prognosis. In an Editorial, Azoulay discusses discuss challenges encountered when communicating .

In an analysis of cross-sectional data from more than 1.6 million Medicare beneficiary hospital admissions, Ibrahim and colleagues compared outcomes and costs for patients who underwent appendectomy, cholecystectomy, colectomy, or hernia repair at 828 critical access hospitals and 3676 non–critical access hospitals. The authors report that among patients undergoing these 4 surgical procedures, patients admitted to critical access hospitals were less medically complex than those admitted to non–critical access hospitals. After adjustment for patient factors, critical access and non–critical access hospitals had similar 30-day mortality rates and critical access hospitals had lower rates of serious complications and lower adjusted Medicare expenditures.

Histologic changes associated with acute gastroesophageal reflux disease (GERD) have not been studied prospectively. In a preliminary study involving 12 patients with severe reflux esophagitis responsive to proton-pump inhibitor (PPI) therapy, Dunbar and colleagues found that stopping PPIs for 2 weeks was associated with histologic features of inflammation and hyperplasia that suggest reflux esophagitis may be cytokine-mediated rather than the result of chemical injury. In an Editorial, Kahrilas discusses the pathogenesis of acute peptic esophagitis.


Venous thromboembolism (VTE) rates are used as a hospital quality measure. An article in JAMA Surgery reported that hospitals with higher rates of inpatient VTE surveillance have higher rates of inpatient VTE but not decreased VTE rates after hospital discharge. In this From The JAMA Network article, Yang and Bilimoria discuss surveillance bias in VTE rate reporting and alternatives for assessing hospital efforts to prevent VTE.

This JAMA Clinical Guidelines Synopsis article summarizes the National Comprehensive Cancer Network and the European Society of Medical Oncology surveillance imaging recommendations for patients with Hodgkin lymphoma and diffuse large B-cell lymphoma in complete remission. The available evidence—primarily from retrospective studies or consensus opinion—suggests asymptomatic patients can be safely observed and imaging studies conducted only when clinically indicated.

Direct-to-consumer advertisements urge patients who take warfarin for atrial fibrillation to ask their physicians about new oral anticoagulants. This Medical Letter on Drugs and Therapeutics article discusses benefits, drawbacks, and costs of direct factor Xa inhibitors (apixaban, edoxaban, and rivaroxaban) and a direct thrombin inhibitor (dabigatran etexilate) compared with warfarin. The direct oral anticoagulants appear to be safer. Head-to-head comparisons of the new drugs are lacking.




Also Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
Please click the checkbox indicating that you have read the full article in order to submit your answers.
Your answers have been saved for later.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.


Some tools below are only available to our subscribers or users with an online account.

0 Citations

Related Content

Customize your page view by dragging & repositioning the boxes below.